OwensDR, MatfinG, MonnierL. Basal insulin analogues in the management of diabetes mellitus: what progress have we made?. Diabetes Metab Res Rev, 2014; 30: 104–19.
2.
MathieuC, HollanderP, Miranda-PalmaB, CooperJ, FranekE, Russell-JonesD, LarsenJ, TamerSC, BainSC. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab, 2013; 98: 1154–62.
3.
MeneghiniL, AtkinSL, GoughSCL, RazI, BlondeL, ShestakovaM, BainS, JohansenT, BegtrupK, BirkelandKI. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily. A 26-week, randomized, open-label, parallel group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care, 2013; 36: 858–64.
4.
ZinmanB, FulcherG, RaoPV, ThomasN, EndahlLA, JohansenT, LindhR, LewinA, RosenstockJ, PingetM, MathieuC. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomized, open-label, phase 2 trial. Lancet, 2011; 377: 924–31.
5.
RosenstockJ, BergenstalRM, BlevinsTC, MorrowLA, PrinceMJ, QuY, SinhaVP, HoweyDC, JacoberSJ. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes. Diabetes Care, 2013; 36: 522–28.
6.
BergenstalRM, RosenstockJ, ArakakiRF, PrinceMJ, QuY, HoweyDC, JacoberSJ. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care, 2012; 35: 2140–47.
7.
MooreMC, SmithMS, SinhaVP, BealsJM, MichaelMD, JacoberSJ, CherringtonAD. Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism. Diabetes, 2014; 63: 494–504.
8.
MorrowL, MuchmoreDB, HompeschM, LudingtonEA, VaughnDE. Comparative pharmacokinetics and insulin action for three rapidly-acting insulin analogs injected subcutaneously with and without hyaluronidase. Diabetes Care, 2013; 36: 273–75.
9.
HeiseT, HaahrH, JensenL, ErichsenL, HompeschM. Faster-acting insulin aspart improves postprandial glycemia vs insulin aspart in patients with type 1 diabetes mellitus (T1DM). Diabetes, 2014; 63(Suppl 1): A34.
